UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
43.62
-1.88 (-4.13%)
At close: Aug 28, 2026, 4:00 PM EDT
44.98
+1.36 (3.12%)
After-hours: Aug 28, 2026, 7:59 PM EDT
UroGen Pharma Revenue
UroGen Pharma had revenue of $72.46M in the quarter ending June 30, 2026, with 199.22% growth. This brings the company's revenue in the last twelve months to $188.73M, up 100.27% year-over-year. In the year 2025, UroGen Pharma had annual revenue of $109.79M with 21.45% growth.
Revenue (ttm)
$188.73M
Revenue Growth
+100.27%
P/S Ratio
11.30
Revenue / Employee
$629,113
Employees
300
Market Cap
2.13B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 109.79M | 19.39M | 21.45% |
| Dec 31, 2024 | 90.40M | 7.69M | 9.29% |
| Dec 31, 2023 | 82.71M | 18.36M | 28.52% |
| Dec 31, 2022 | 64.36M | 16.32M | 33.96% |
| Dec 31, 2021 | 48.04M | 36.24M | 307.17% |
| Dec 31, 2020 | 11.80M | 11.78M | 65,450.00% |
| Dec 31, 2019 | 18.00K | -1.11M | -98.40% |
| Dec 31, 2018 | 1.13M | -7.03M | -86.17% |
| Dec 31, 2017 | 8.16M | -9.37M | -53.46% |
| Dec 31, 2016 | 17.53M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 1.97B |
| Harmony Biosciences Holdings | 959.90M |
| Aurinia Pharmaceuticals | 311.51M |
| Maravai LifeSciences Holdings | 208.78M |
| Mesoblast | 120.25M |
| Xencor | 104.97M |
| Nanobiotix | 38.27M |
| Zenas BioPharma | 1.00M |
URGN News
- 9 days ago - IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies - PRNewsWire
- 9 days ago - UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline - GlobeNewsWire
- 12 days ago - UroGen Pharma submits UGN-103 NDA to FDA - TheFly
- 12 days ago - UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC - GlobeNewsWire
- 23 days ago - UroGen Pharma price target raised to $60 from $50 at Oppenheimer - TheFly
- 23 days ago - UroGen Pharma price target raised to $58 from $42 at Guggenheim - TheFly
- 23 days ago - UroGen Pharma price target raised to $75 from $45 at H.C. Wainwright - TheFly
- 24 days ago - UroGen Pharma price target raised to $60 from $50 at TD Cowen - TheFly